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Abstract 
Objective: Lower serum albumin (sAlb) has been associated with an increased risk of mortality 
and AIDS among people living with HIV and may be associated with the development of serious 
non-AIDS events (SNAEs). We evaluated the long-term association between sAlb and the risk of 
SNAEs. 
Design: Prospective multinational cohort study. 
Methods: D:A:D participants without SNAEs were followed from first routine sAlb value to the 
first of a new SNAE [cardiovascular disease (CVD), end-stage liver disease (ESLD), end-stage 
renal disease (ESRD), non-AIDS malignancy (NADM), death from non-AIDS cause], AIDS-
death, 6 months after last visit or 01/02/2016. Poisson regression was used to determine 
associations between sAlb and a new i) SNAE, ii) CVD or iii) NADM event, with adjustment for 
potential confounders. Models additionally tested whether the associations were modified by 
age, follow-up time, smoking status, CD4 and viral load. 
Results: Of 16,350 participants (71.8% male, median age 44 years) 1,463 developed a SNAE 
(371 CVD, 200 ESLD, 40 ESRD, 553 NADM, 299 deaths from other non-AIDS causes) over 
80,264 person-years. Increased sAlb was associated with a decreased risk of an SNAE (adjusted 
rate ratio (aRR) per 5g/L: SNAE 0.79 [95%CI: 0.76, 0.83]; CVD 0.87 [0.80, 0.94]; NADM 0.88 
[0.82, 0.95]). The association did not appear to wane with additional years of follow-up (p-
interaction=0.79) but was stronger for current smokers than for never smokers (p-
interaction<0.01). 
Conclusions: sAlb is a durable risk factor for SNAE. Future studies are needed to determine the 
mechanism underlying this association and to evaluate the value of sAlb in predictive tools. 
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INTRODUCTION 
Exploring novel associations between biomarkers and serious non-AIDS events (SNAE) may 
inform disease pathogenesis. Low serum albumin (sAlb) has consistently been associated with 
AIDS progression and all-cause mortality in people living with HIV (PLWH) [1-6]. Moreover, 
the association of sAlb with SNAE was recently assessed in the INSIGHT START Study [7]. 
SAlb was independently associated with SNAE over the short-term and, potentially, over the 
longer term. Due to a limited sample size and duration of follow-up, this study was not powered 
to detect associations with specific SNAE, assess important effect modifiers, or to determine the 
duration over which the association remained present.  
Using data from the Data on Adverse Events of Antiretroviral Drugs (D:A:D) Study we aimed to 
undertake a detailed evaluation of the association between sAlb and SNAE in a larger and more 
heterogeneous study population with longer follow-up.  
METHODS 
Study design 
The D:A:D Study is an observational study following approximately 50,000 PLWH from 11 
cohorts in Europe, USA and Australia. Collected data include information on socio-demographic 
factors, HIV-related factors including AIDS events and antiretroviral treatment (ART) regimens, 
and other non-AIDS risk factors.  
A SNAE was systematically collected (https://www.chip.dk/Studies/DAD/Study-Documents) 
and defined as CVD (myocardial infarction, stroke, invasive cardiovascular procedure or death 
from CVD); end-stage renal disease (ESRD) or death from renal disease; end-stage liver disease 
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(ESLD) or death from ESLD; non-AIDS-defining malignancies (NADMs, except for basal cell 
or squamous cell skin cancer) or death from cancer; and any other non-AIDS death.  
We excluded cohorts that did not provide any or sparse sAlb data (online supplement M1, 
http://links.lww.com/QAD/B297). We selected a baseline date for each cohort which reflected 
the time at which the coverage of sAlb measurements increased to a level that suggested routine 
monitoring. As the systematic collection of some SNAE did not commence until 1st February 
2004, each cohort-specific baseline date was set to the later of this date or the date of routine 
sAlb monitoring. The date of the closest sAlb measurement to this cohort-specific date (as long 
as the sAlb had been measured less than one year prior to this date) was taken to be the 
individual baseline date. Individuals without a sAlb measurement in this window were excluded, 
as were those who already had a SNAE at their baseline.   
Statistical methods 
Study participants were followed from baseline to the date of each endpoint; follow-up for each 
person was censored on the date of an AIDS death, six months after the last clinic visit or on 1st 
February 2016, whichever occurred earliest.  Follow-up times for analyses of the CVD and 
NADM endpoints were additionally censored on the date of a non-CVD/non-NADM SNAE. 
Poisson regression was used to model the rate of the three endpoints; unadjusted and adjusted 
rate ratios (RR/aRR) and 95% confidence intervals (CIs) were computed. We considered a fixed 
model with covariates defined on the baseline date.   
Selection of confounders for inclusion in multivariable models was based on available 
information about the relation between sAlb and SNAE. Covariates that were included were 
participating cohort, gender, risk group, race, age, body-mass index (BMI), smoking status 
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(current smoker, ex-smoker, never smoker, unknown), dyslipidaemia (total cholesterol (TC) ≥6.2 
mmol/l, high-density lipoprotein cholesterol (HDL-C) ≤0.9 mmol/l, TC:HDL-C ratio ≥6.5 or 
receipt of lipid lowering drug), ALT and estimated glomerular filtration rate (eGFR)(Cockcroft-
Gault equation), hepatitis C-virus (HCV)(positivity by anti-HCV and/or HCV RNA positive), 
hepatitis B-virus (HBV)(positivity by HBsAg, HBeAg  or HBV-DNA positive/anti-HBe 
positive), CD4 count, viral load (VL)<50 copies/ml, current exposure to each antiretroviral class. 
All variables were continuous unless specified otherwise. 
We also assessed interactions between i) sAlb and age; ii) sAlb and cigarette smoking; iii) sAlb 
and follow-up time; iv) sAlb and baseline CD4 count; and v) sAlb and the latest HIV RNA (as a 
time-updated covariate). Analyses were conducted in SAS version 9.3. 
RESULTS 
Of the 33,750 potentially eligible individuals, 16,350 had a baseline sAlb measurement and were 
free of SNAE at this time. The characteristics of the individuals excluded at this stage did not 
differ substantially from those of the included participants (male 74.1% vs. 71.8%; heterosexual 
35.5% vs. 36.4%; white ethnicity 50.0% vs. 50.5%; median age 38 vs. 37 years; previous 
exposure to ART 62.4% vs. 63.3%, median CD4 cell count 408 vs. 420 cells/mm3). A detailed 
description of study participants is provided in online supplement M2, 
http://links.lww.com/QAD/B297.    
Study participants were followed for a total of 80,264 person-years (PYRS), during which 1463 
SNAE were observed. This included 371 (25.4%) CVD events, 553 (37.8%) NADM events, 200 
(13.7%) ESLD events, 40 (2.7%) ESRD events and 299 (20.4%) deaths from other SNAE. 
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PYRS, event rates, and number of events stratified by sAlb levels are depicted in online 
supplement M3, http://links.lww.com/QAD/B297.   
Lower sAlb was associated with all events considered and RRs were only modified slightly after 
adjustment (Table 1). Moreover, various strata of lower levels of sAlb appeared to be associated 
with higher SNAE rates suggesting a linear association. Whilst associations were numerically 
weaker for the CVD and NADM endpoints, the trend for a higher event rate in those with lower 
sAlb levels was still apparent (online supplementary M2, http://links.lww.com/QAD/B297).  
We tested several interactions (Figure 1). The association between sAlb and SNAE was slightly 
stronger in younger individuals (p-interaction<0.001). For SNAE the association with sAlb 
seemed to differ by baseline CD4+ cell count with the strongest effect seen among individuals 
with CD4+ cell counts below 200 cells/mm3 (p-interaction<0.001). The association between sAlb 
and SNAE was still evident six years after baseline sAlb measurement in the fully adjusted 
model and there was no evidence that the association between sAlb and SNAE changed over 
time (p-interaction=0.79). We found evidence for an interaction between smoking and sAlb with 
a stronger association for current smokers compared to never smokers (aRR 0.76 [95%CI: 0.73-
0.80] vs aRR 0.87 [95%CI: 0.80-0.95], p<0.01). Finally, analyses revealed some effect 
modification with the latest viral load for the SNAE, with associations being slightly stronger in 
those with a non-suppressed viral load (p-interaction<0.001). 
DISCUSSION 
We found a strong association between lower sAlb and SNAE. This observation was consistent 
across different SNAE and did not appear to wane over time since sAlb measurement. The 
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association between sAlb and SNAE appeared to be stronger in younger individuals and in 
current smokers.  
Several studies have found an association between sAlb and all-cause mortality in PLWH. One 
of the earliest studies from the Women’s Interagency HIV Study suggested that sAlb could be 
associated with non-AIDS causes of mortality, as sAlb was found to be a more strongly 
associated with mortality in individuals with high CD4 counts [3]. A US veterans study 
confirmed this and noted a strong independent association between sAlb and atherosclerotic 
CVD events and heart failure [5]. SAlb was also recently shown to be associated with SNAE in 
the START study. Our study confirmed these findings and demonstrated that sAlb was 
associated with both CVD and NADM.  
Several factors may confound our observations. Although low sAlb is commonly regarded as a 
marker of nutritional status, it is poorly associated with other measures of nutritional status in the 
general population and in PLWH [8, 9]. Other causes of low sAlb may include liver disease 
(decreased synthesis), enhanced turnover resulting from either increased catabolism or enhanced 
loss of albumin into the urine or intestine [10], or trans-capillary loss due to increased vascular 
permeability [11]. The acute phase response, of which interleukin (IL)-6 is a potent inducer, to 
infectious conditions, neoplastic growth, or immunological disorders, is also associated with 
inhibition of liver protein synthesis in animal studies [12]. A lowering of sAlb may therefore 
reflect the chronic inflammation that has been associated with HIV infection [13]. In the START 
study, however, sAlb was associated with SNAE even after adjusting for IL-6 levels [7]. A low 
sAlb level might be a consequence of other pathways of immune activation that may be less 
directly associated with the inflammatory marker IL-6. Moreover, the neonatal Fc receptor, 
expressed in many different cell types and induced by pro-inflammatory cytokines like TNF-α 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
and IL-1β [14],  protects sAlb from degradation [15]. Finally, sAlb may exert a protective effect 
due to antioxidant activity, binding capacity of endogenous and exogenous compounds (e.g. fatty 
acids and carcinogens) [16], or its anti-thrombotic effects [17].  
We also showed that sAlb was associated with disease endpoints even when the level was 
measured six years before the occurrence of a SNAE and when sAlb was within the range of 
levels commonly considered as normal (>35 g/L). Individuals with sAlb levels of 35-40 g/L 
(low-normal), controlling for other factors, were more likely to experience a SNAE than 
individuals with levels of 40-45 g/L (high-normal). SAlb even seemed to exert a protective effect 
at high levels (>45 g/L). Thus, the association with SNAE appeared to be linear with no obvious 
threshold effect.  
A few interventions may cause changes to sAlb levels. Initiation of cART was associated with 
higher sAlb concentration during follow-up when compared to participants who deferred cART 
initiation [7]. Smoking cessation has been associated with increases in sAlb with levels changing 
towards those of never smokers within five years [18]. We showed that the association between 
sAlb and SNAE was strongest in current smokers, in line with earlier studies from the general 
population [18, 19]. Mechanisms underlying the potential effects of interventions on sAlb levels 
or in which ways factors modify the association between sAlb and SNAE are unknown. As the 
correlation between cumulative smoking and sAlb was weak, it was previously suggested that 
those smokers with lowest sAlb levels were those with the greatest inflammatory response to 
smoking [18]. Consistent with this, newer evidence shows that smoking is associated with 
extensive alterations in systemic markers of inflammation of which many revert back to levels of 
never smokers after smoking cessation [20]. sAlb levels may consequently be a proxy for 
susceptibility to the effect of noxious stimuli, such as smoking, but potentially also to 
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inflammation associated with HIV. Accordingly, we also observed an association between sAlb 
and SNAE in those who reported never smoking in contrast to studies from the general 
population [18, 19], and we showed that viral suppression modified the association between sAlb 
and SNAE, which indicate that the association is not driven completely independent of HIV.  
Our study has limitations. First, SAlb concentrations were measured irregularly in the 
contributing cohorts. To avoid the confounding effect of increased monitoring in sick 
individuals, we considered a fixed timepoint analysis. Secondly, not all eligible individuals had a 
sAlb measurement, which may have introduced selection bias, although we observed 
characteristics of individuals with and without sAlb measurements to be similar.  
In conclusion, sAlb was found to be independently associated with SNAE, including CVD and 
NADM. This association did not appear to wane over time and was strongest in current smokers. 
The pathophysiology underlying the relationship between sAlb and SNAE, and its effect 
modifiers, are poorly understood, and warrants further mechanistic investigation. 
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The multi-centre study group, EuroSIDA (national coordinators in parenthesis). 
Argentina: (M Losso), M Kundro, Hospital JM Ramos Mejia, Buenos Aires.  
Austria: (B Schmied), Pulmologisches Zentrum der Stadt Wien, Vienna; R Zangerle, Medical 
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Esposito, I Mazeu, C Mussini, Università Modena, Modena; F Mazzotta, A Gabbuti, Ospedale S 
Maria Annunziata, Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, Rome; M 
Zaccarelli, A Antinori, R Acinapura, M Plazzi, Istituto Nazionale Malattie Infettive Lazzaro 
Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti, Ospedale San Raffaele, Milan; M Galli, 
A Ridolfo, Osp. L. Sacco, Milan. 
Latvia: (B Rozentale), Infectology Centre of Latvia, Riga.  
Lithuania: (V Uzdaviniene) Vilnius University Hospital Santariskiu Klinikos, Vilnius; R 
Matulionyte, Center of Infectious Diseases, Vilnius University Hospital Santariskiu Klinikos, 
Vilnius.  
Luxembourg: (T Staub), R Hemmer, Centre Hospitalier, Luxembourg.  
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Amsterdam. 
Norway: (V Ormaasen), A Maeland, J Bruun, Ullevål Hospital, Oslo.  
Poland: (B Knysz), J Gasiorowski, M Inglot, Medical University, Wroclaw; A Horban, E 
Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; R Flisiak,  A Grzeszczuk, Medical 
University, Bialystok; M Parczewski, K Maciejewska, B Aksak-Was, Medical Univesity, 
Szczecin; M Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; T 
Smiatacz, M Gensing, Medical University, Gdansk; E Jablonowska, E Malolepsza, K Wojcik, 
Wojewodzki Szpital Specjalistyczny, Lodz; I Mozer-Lisewska, Poznan University of Medical 
Sciences, Poznan. 
Portugal: (L Caldeira), Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, 
Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.  
Romania: (R Radoi), C Oprea, Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, 
Bucarest.  
Russia: (A Panteleev), O Panteleev, St Petersburg AIDS Centre, St Peterburg; A Yakovlev, 
Medical Academy Botkin Hospital, St Petersburg; T Trofimora, Novgorod Centre for AIDS, 
Novgorod, I Khromova, Centre for HIV/AIDS & and Infectious Diseases, Kaliningrad; E 
Kuzovatova, Nizhny Novgorod Scientific and Research Institute of Epidemiology and 
Microbiology named after Academician I.N. Blokhina, Nizhny Novogrod; E Borodulina, E 
Vdoushkina, Samara State Medical University, Samara. 
Serbia: (D Jevtovic), The Institute for Infectious and Tropical Diseases, Belgrade.  
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Slovenia: (J Tomazic), University Clinical Centre Ljubljana, Ljubljana.  
Spain: (JM Gatell), JM Miró, Hospital Clinic Universitari de Barcelona, Barcelona; S Moreno, J. 
M. Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, C Tural, J Puig, I 
Bravo, Hospital Germans Trias i Pujol, Badalona; P Domingo, M Gutierrez, G Mateo, MA 
Sambeat, Hospital Sant Pau, Barcelona; JM Laporte, Hospital Universitario de Alava, Vitoria-
Gasteiz.  
Sweden:  (K Falconer), A Thalme, A Sonnerborg, Karolinska University Hospital, Stockholm; A 
Blaxhult, Venhälsan-Sodersjukhuset, Stockholm; L Flamholc, Malmö University Hospital, 
Malmö. 
Switzerland: (A Scherrer), R Weber, University Hospital Zurich; M Cavassini, University 
Hospital Lausanne; A Calmy, University Hospital Geneva; H Furrer, University Hospital Bern; 
M Battegay, University Hospital Basel; P Schmid, Cantonal Hospital St. Gallen. 
Ukraine:  A Kuznetsova, Kharkov State Medical University, Kharkov; G Kyselyova, Crimean 
Republican AIDS centre, Simferopol; M Sluzhynska, Lviv Regional HIV/AIDS Prevention and 
Control CTR, Lviv. 
United Kingdom: (B Gazzard), St. Stephen's Clinic, Chelsea and Westminster Hospital, London; 
AM Johnson, E Simons, S Edwards, Mortimer Market Centre, London; A Phillips, MA Johnson, 
A Mocroft, Royal Free and University College Medical School, London (Royal Free Campus); C 
Orkin, Royal London Hospital, London; J Weber, G Scullard, Imperial College School of 
Medicine at St. Mary's, London; A Clarke, Royal Sussex County Hospital, Brighton; C Leen, 
Western General Hospital, Edinburgh. 
The following centers have previously contributed data to EuroSIDA: 
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Infectious Diseases Hospital, Sofia, Bulgaria 
Hôpital de la Croix Rousse, Lyon, France 
Hôpital de la Pitié-Salpétière, Paris, France 
Unité INSERM, Bordeaux, France 
Hôpital Edouard Herriot, Lyon, France 
Bernhard Nocht Institut für Tropenmedizin, Hamburg, Germany 
1st I.K.A Hospital of Athens, Athens, Greece 
Ospedale Riuniti, Divisione Malattie Infettive, Bergamo, Italy 
Ospedale di Bolzano, Divisione Malattie Infettive, Bolzano, Italy 
Ospedale Cotugno, III Divisione Malattie Infettive, Napoli, Italy 
Dérer Hospital, Bratislava, Slovakia 
Hospital Carlos III, Departamento de Enfermedades Infecciosas, Madrid, Spain 
Kiev Centre for AIDS, Kiev, Ukraine 
Luhansk State Medical University, Luhansk, Ukraine 
Odessa Region AIDS Center, Odessa, Ukraine                                                                                                         
HivBivus (Sweden): 
Central coordination: L. Morfeldt, G. Thulin, A. Sundström. 
Participating physicians (city): B. Åkerlund (Huddinge); K. Koppel, A. Karlsson (Stockholm); L. 
Flamholc, C. Håkangård (Malmö). 
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The ICONA Foundation (Italy): 
BOARD OF DIRECTORS 
A d’Arminio Monforte (President), A Antinori, A Castagna, F Castelli, R Cauda, G Di Perri, M 
Galli, R Iardino, G Ippolito, GC Marchetti, CF Perno, F von Schloesser, P Viale  
SCIENTIFIC SECRETARY 
A d’Arminio Monforte, A Antinori, A Castagna, F Ceccherini-Silberstein, A Cozzi-Lepri, E 
Girardi, S Lo Caputo, C Mussini, M Puoti 
STEERING COMMITTEE  
M Andreoni, A Ammassari, A Antinori, C Balotta, A Bandera, P Bonfanti, S Bonora, M Borderi, 
A Calcagno, L Calza, MR Capobianchi, A Castagna, F Ceccherini-Silberstein, A Cingolani, P 
Cinque, A Cozzi-Lepri, A d’Arminio Monforte, A De Luca, A Di Biagio, E Girardi, N Gianotti, 
A Gori, G Guaraldi, G Lapadula, M Lichtner, S Lo Caputo, G Madeddu, F Maggiolo, G 
Marchetti, S Marcotullio, L Monno, C Mussini, S Nozza, M Puoti, E Quiros Roldan, R Rossotti, 
S Rusconi, MM Santoro, A Saracino, M Zaccarelli. 
STATISTICAL AND MONITORING TEAM 
A Cozzi-Lepri, I Fanti, L Galli, P Lorenzini, A Rodano, M Shanyinde, A Tavelli 
BIOLOGICAL BANK INMI  
F Carletti, S Carrara, A Di Caro, S Graziano, F Petrone, G Prota, S Quartu, S Truffa 
PARTICIPATING PHYSICIANS AND CENTERS 
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Italy A Giacometti, A Costantini, V Barocci (Ancona); G Angarano, L Monno, C Santoro (Bari); 
F  Maggiolo, C Suardi (Bergamo); P Viale, V Donati, G Verucchi (Bologna); F Castelli, C 
Minardi, E Quiros Roldan (Brescia); T Quirino, C Abeli (Busto Arsizio); PE  Manconi, P Piano 
(Cagliari); B Cacopardo, B Celesia (Catania);  J Vecchiet, K Falasca (Chieti); A Pan, S 
Lorenzotti (Cremona); L Sighinolfi, D Segala (Ferrara); F Mazzotta, F Vichi (Firenze); G 
Cassola, C Viscoli, A Alessandrini, N Bobbio, G Mazzarello (Genova); C Mastroianni, V Belvisi 
(Latina); P Bonfanti, I Caramma (Lecco); A Chiodera, P Milini (Macerata); A d’Arminio 
Monforte, M Galli, A Lazzarin, G Rizzardini, M Puoti, A Castagna, G Marchetti, MC Moioli, R 
Piolini, AL Ridolfo, S Salpietro, C Tincati, (Milano); C Mussini, C Puzzolante (Modena); A 
Gori, G Lapadula (Monza); N Abrescia, A Chirianni, G Borgia, R Orlando, G Bonadies, F Di 
Martino, I Gentile, L Maddaloni (Napoli); AM Cattelan, S Marinello (Padova); A Cascio, C 
Colomba (Palermo); F Baldelli, E Schiaroli (Perugia);  G  Parruti, F Sozio (Pescara); G Magnani, 
MA Ursitti (Reggio Emilia); M Andreoni, A Antinori, R Cauda, A Cristaudo, V Vullo, R 
Acinapura, G Baldin, M Capozzi, S Cicalini, A Cingolani, L Fontanelli Sulekova, G Iaiani, A 
Latini, I Mastrorosa, MM Plazzi, S Savinelli, A Vergori (Roma); M Cecchetto, F Viviani 
(Rovigo); G Madeddu, P Bagella (Sassari); A De Luca, B Rossetti (Siena);  A Franco, R Fontana 
Del Vecchio (Siracusa); D Francisci, C Di Giuli (Terni); P Caramello, G Di Perri, S Bonora, GC 
Orofino, M Sciandra (Torino); M Bassetti, A Londero (Udine); G Pellizzer, V Manfrin (Vicenza) 
G Starnini, A Ialungo(Viterbo). 
Nice HIV Cohort (France):  
Central coordination: C. Pradier*, E. Fontas, K. Dollet, C. Caissotti.  
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Participating physicians: P. Dellamonica, E. Bernard, J. Courjon, E. Cua, F. De Salvador-
Guillouet, J.Durant, C. Etienne, S. Ferrando, V. Mondain-Miton, A. Naqvi, I. Perbost,S. Pillet , 
B. Prouvost-Keller, P. Pugliese, V. Rio, K. Risso, P.M. Roger. 
SHCS (Swiss HIV Cohort Study, Switzerland): 
The data are gathered by the Five Swiss University Hospitals, two Cantonal Hospitals,15 
affiliated hospitals and 36 private physicians (listed in http://www.shcs.ch/180-health-care-
providers). 
Members of the Swiss HIV Cohort Study: 
Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A, Cavassini M, 
Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of the Clinical 
and Laboratory Committee), Fux CA, Günthard HF (President of the SHCS), Haerry D (deputy 
of "Positive Council"), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser 
O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, 
Marzolini C, Metzner KJ, Müller N, Nicca D, Pantaleo G, Paioni P, Rauch A (Chairman of the 
Scientific Board), Rudin C (Chairman of the Mother & Child Substudy), Scherrer AU (Head of 
Data Centre), Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Wandeler G, Weber 
R*, Yerly S.  
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Table 1: Unadjusted and adjusted association between baseline sAlb value and a) any 
SNAE, b) any CVD event, and c) any NADM, obtained from Poisson regression analysis. 
 
 Unadjusted  Adjusted  
 RR (95% CI) p-value aRR (95% CI) P-value 
a) Any SNAE     
Albumin (g/L) <30 4.57 (3.74, 
5.58) 
<0.0001 3.57 (2.89, 
4.40) 
<0.0001 
>30, <35 2.52 (2.07, 
3.07) 
<0.0001 2.30 (1.88, 
2.82) 
<0.0001 
>35, <40 1.50 (1.31, 
1.71) 
<0.0001 1.33 (1.16, 
1.52) 
<0.0001 
>40, <45 Ref. - Ref. - 
>45, <50 0.77 (0.67, 
0.89) 
<0.001 0.82 (0.71, 
0.95) 
<0.01 
>50 0.63 (0.45, 
0.89) 
<0.01 0.73 (0.51, 
1.03) 
0.07 
Albumin (continuous, per 5g/L) 0.75 (0.73, 
0.78) 
<0.0001 0.79 (0.76, 
0.82) 
<0.0001 
b) Any CVD event     
Albumin 
(g/L)  
<30 1.12 (0.55, 
2.29) 
0.75 1.23 (0.60, 
2.51) 
0.58 
>30, <35 1.79 (1.16, 
2.74) 
<0.01 2.33 (1.50, 
3.62) 
<0.001 
>35, <40 1.34 (1.03, 
1.75) 
0.03 1.31 (1.00, 
1.71) 
0.05 
>40, <45 Ref. - Ref. - 
>45, <50 0.83 (0.64, 
1.07) 
0.15 0.81 (0.62, 
1.07) 
0.13 
>50 0.60 (0.30, 
1.17) 
0.13 0.63 (0.32, 
1.24) 
0.18 
Albumin (continuous, per 5g/L) 0.87 (0.80, 
0.94) 
<0.001 0.87 (0.80, 
0.94) 
<0.001 
c) Any NADM event     
Albumin 
(g/L) 
<30 2.44 (1.63, 
3.66) 
<0.0001 1.98 (1.28, 
3.04) 
<0.01 
>30, <35 1.64 (1.14, 
2.36) 
<0.01 1.54 (1.05, 
2.24) 
0.03 
>35, <40 1.12 (0.89, 
1.41) 
0.32 1.00 (0.79, 
1.26) 
0.98 
>40, <45 Ref. - Ref. - 
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>45, <50 0.84 (0.68, 
1.04) 
0.11 0.92 (0.74, 
1.14) 
0.44 
>50 0.80 (0.49, 
1.29) 
0.35 0.94 (0.58, 
1.53) 
0.81 
Albumin (continuous, per 5g/L) 0.84 (0.79, 
0.89) 
<0.0001 0.88 (0.82, 
0.95) 
<0.001 
 
1Adjusted for participating cohort, gender, risk group, race, and the following covariates defined 
at baseline: age, BMI, smoking status, dyslipidaemia, total cholesterol, ALT, eGFR, HCV, HBV, 
CD4, VL<50 copies/ml, current exposure to NRTIs, PIs, NNRTIs and INSTIs. Abbreviations: 
CVD, cardiovascular disease; NADM, non-AIDS defining malignancy; RR, rate ratio; SNAE, 
serious non-AIDS event. 
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